Citations

Clear

3942 citation(s) found for "To, Van".

Dynamic MRI of Fluid and Solute Transportation across the Arachnoid Barrier in the Human Meninges
Li, Yinghao , Sun, Yuanqi, Paez, Adrian , Xu, Gaoqiang , Pillai, Jay J. , Iliff, Jeffrey J., Ganji, Sandeep , Knutsson, Linda, Zijl, Peter C. M. Van, Calabresi, Peter A., Sun, Yuanqi , Knutsson, Linda , Sun, Yang-bai , Sun, Yuanqi , Iliff, Jeffrey , Ganji, Sandeep K , Knutsson, Linda , Calabresi, Peter A , Hua, Jun , Pillai, Jay J , Iliff, Jeffrey J. , Zijl, Peter C.M. van , Kamson, David , Calabresi, Peter A.

Mayo Clinic

Radiology | February 24, 2026 | Volume: 318 | Issue: 2 | Pages: No page available

10.1148/radiol.252393 | PMID 41733473 Get It

Dynamic fluid and solute transportation across the arachnoid barrier in the meninges of healthy participants was measured by tracking intravenous gadolinium-based contrast agent entering cerebrospinal fluid from dural blood vessels using dynamic dual-spin-echo perfusion MRI.
Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches
DeFilippis, Ersilia M. , Cheng, Richard K., Donald, E., Dunlay, Shannon M. , Evangelista, Lorraine S. , Kamdar, Forum , Khazanie, Prateeti , Mohammed, Selma F. , Rossi, Ana P. , Spall, Harriette G.C. Van , Breathett, Khadijah , Cheng, Richard K. , DeFilippis, Ersilia M. , Donald, Elena M , Van Spall, Harriette G C , Verma, Aradhana , Breathett, Khadijah , Dunlay, Shannon , Cheng, Richard , Mohammed, Selma , Rossi, Ana

Mayo Clinic

Circulation: Heart Failure | February 24, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.125.013747 | PMID 41730520 Get It

Kidney dysfunction after heart transplantation (HT) is associated with significant morbidity and mortality. Recipient and perioperative factors may all influence the risk of kidney injury. Furthermore, data suggest that the incidence of kidney dysfunction, both acute and chronic, is increasing after the implementation of the United States’ 2018 allocation system due to increasing use of temporary mechanical circulatory support and changing recipient characteristics. While data are robust regarding nephroprotective therapies such as renin-angiotensin-aldosterone system inhibition and SGLT2i (sodium-glucose cotransporter 2 inhibitors) to minimize the progression of chronic kidney disease in patients with heart failure, data in HT recipients are beginning to emerge. This state-of-the-art review will critically examine the existing literature regarding the epidemiology of kidney dysfunction after HT, mitigation strategies for acute kidney injury and chronic kidney disease, including pharmacotherapeutics, the need for kidney transplantation after HT, and practical next steps for the larger HT community.
From chronology to morphology: toward objective image-guided assessment of endoscopic ultrasound-guided drainage for walled-off necrosis
Vanella, Giuseppe, Marzocca, G. , Frigo, Francesco , Bronswijk, Michiel , Wanrooij, Roy L.J. van, Chandrasekhara, Vinay, Merwe, Schalk Van der, Capurso, Gabriele, Arcidiacono, Paolo Giorgio , Wanrooij, Roy L.J. van , Merwe, Van der , Arcidiacono, Paolo Giorgio , van Wanrooij, Roy L J , Vanella, Giuseppe , Chandrasekhara, Vinay , Capurso, Gabriele

Mayo Clinic

Endoscopy | February 20, 2026 | Volume: 58 | Issue: 03 | Pages: 316-317

10.1055/a-2749-8235 | PMID 41720137 Get It

Abstract PS4-09-08: Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical Trials
Horton, S. L., Idossa, D. A., Hewitt, K. C., Perlmutter, Jane , Veer, L. Van't, Hylton, N., Borowsky, A., Symmans, F, Yee, Don, Yau, C., Pohlmann, P., Boughey, JC , Esserman, L. J., Idossa, Damé , Hewitt, Kyle , Hylton, N. M., Borowsky, A. D., Symmans, W. Fraser , Yee, D., Yau, C., Pohlmann, P. R., Esserman, L. J.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS4-09-08-PS4-09-08

10.1158/1557-3265.sabcs25-ps4-09-08 Get It

Abstract Introduction Cancer clinical trials have historically faced challenges in achieving fully representative trial population, particularly in terms of including patients from diverse ethnic and racial groups, those with low socioeconomic status, and those living in rural regions. This has contributed to inequities in access to novel therapeutic options. Background The I-SPY adaptive platform trials have prioritized diversity since inception, consistently enrolling in >10% of trial patients being Black and/or Hispanic individuals. The majority of participating institutions in the I-SPY 2.2 study are academic or large well-resourced health systems. In 2023, the I-SPY ACCESS (Achieving Cancer Clinical Trial Equity in Socioeconomically Diverse Sites) Initiative was launched to enhance representation by engaging and involving nontraditional trial sites- such as safety-net hospitals, community cancer centers, and rural cancer centers- that serve historically excluded patient populations. Methods The I-SPY ACCESS Initiative offers customized and personalized tailored support to under-resourced sites. This includes comprehensive feasibility and readiness assessments, onboarding guidance, enhanced site-specific training, centralized institutional review board (IRB) navigation, site peer mentorship, and educational materials for both patient and provider. Additionally, patients gain access to I-SPY advocate peer trial navigators. Sites are provided culturally responsive patient education tools- including multilingual brochures, a dedicated patient website, and content co-developed with community partners. A Clinical Trial Navigator supports both patients and sites, helping to locate logistical, social, and trial specific resources.Tools such as virtual Clinical Research Coordinators (vCRC's) and OneSource technology are deployed strategically based on assessed site need and resource availability. OneSource is an innovative platform that enables direct extraction of clinical data from electronic health records into trial databases, reducing site workload and improving data quality. Funding models are currently being explored to extend OneSource and vCRC services across more ACCESS sites. In the future, there are plans to pilot financial navigation services and integrative care resources for all patients enrolled in I-SPY with particular focus on those enrolled at ACCESS sites. Results and Progress As of June 2025, seven sites have been assessed as ACCESS sites for I-SPY 2.2, with two sites having successfully completed activation and currently enrolling participants. Beginning in mid-2024, one DCIS RECAST ACCESS site has been activated and 11 additional sites are in the onboarding process. The modest pace of I-SPY 2.2 activation reflects the complexity and operational demands associated with resource-intensive platform trial. In contrast, the DCIS RECAST protocol was designed with a lower burden, facilitating easier implementation by under-resourced sites, reflected by increased interest in the study among ACCESS sites. The ACCESS framework is being explored for potential future application in the Pre I-SPY Phase 1 platform trial, particularly considering the historical underrepresentation of such sites in the early-phase clinical research. Conclusion and Future Goals The I-SPY ACCESS initiative demonstrates that investing in thoughtful, innovative, and effective means for trial delivery, as well as incorporating community-based support, can strengthen representation in complex, adaptive breast cancer trials. The initiative offers a flexible, equity-driven framework that is impactful now and scalable for future innovation in oncology research. Citation Format: S. L. Horton, D. A. Idossa, K. C. Hewitt, J. Perlmutter, L. Van't Veer, N. Hylton, A. Borowsky, F. Symmans, D. Yee, C. Yau, P. Pohlmann, J. Boughey, L. Esserman. Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical Trials [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-09-08.
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
Giridhar, K. V., Goetz, M. P., Yau, C., Wallace, A. M., Boughey, J., Arora, M., Stringer-Reasor, E., Nangia, C., Gallagher, C., Elias, A., Trivedi, M. S., Omene, Coral , Veer, L. van 't, Swigart, L. Brown, Hirst, G. L., Symmans, W. F., Borowsky, A. D., Hylton, N., Vakalvas, C., Wei, M., Reid, J. M., Alhafaji, S., Chen, N., Mukhtar, R. M., Huppert, L., Opopade, O., Esserman, L. J., Chein, Aung, Giridhar, K. V., Goetz, M. P., Yau, C., Wallace, A.M., Falkson, Carla I. , Boughey, J. C., Stringer-Reasor, Erica , Nangia, C., Elias, A., Zimmer, Alexandra S. , Trivedi, M. S., Veer, L. J. van 't, Swigart, Lamorna Brown , Hirst, G. L., Symmans, W. Fraser , Borowsky, A. D., Onishi, Natsuko , Hylton, N. M., Wei, M., Reid, J. M., Alkhafaji, Silver , Chen, N., Mukhtar, R., Huppert, L. A., Esserman, L. J.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-07-10-PS3-07-10

10.1158/1557-3265.sabcs25-ps3-07-10 Get It

Abstract Background: (Z)-endoxifen (ENDX) is an oral SERM that dually targets ERα (> 5 ng/ml) and PKCβ1 (>500 ng/ml). It has been tested in the endocrine resistant setting at doses of 20-360 mg/day; however, the optimal dose in an endocrine naïve population is not defined. We explored 10 mg/day dose of neoadjuvant ENDX in the Endocrine Optimization Pilot (EOP) of I-SPY2. Methods: EOP eligibility included pts with Stage II/III HR+ HER2- breast cancer, MammaPrint (MP) low. Pts with MP High1 scores were eligible if clinically node-negative. Pts received ENDX 10 mg orally once daily for 6 cycles (each cycle = 28 days). Premenopausal pts started ovarian function suppression on cycle 2, day 1. ENDX was continued until the day prior to surgery. The primary study endpoint was feasibility, defined as >75% of pts completing >75% of ENDX. Baseline (T0), 3-wk (T1) biopsies, and the surgical specimen (T3) were assessed centrally for Ki-67. Rates of modified preoperative endocrine prognostic index (mPEPI) 0 were reported, defined as pT1-2 pN0, Ki67< 2.7%, or pathologic complete response. A genomic index for sensitivity to endocrine therapy (SET) index was done at T0. Breast MRI measurement of functional tumor volume (FTV) was performed at T0, T1, 12 weeks (T2), and pre-operatively (T3). Blood was collected for tumor informed ctDNA at T0, T1, T2, T3 and for pharmacokinetic (PK) steady state concentrations (Css) at T1. Safety data using CTCAE V5 is reported. Results: Between March 2023 and May 2024, 20 pts were enrolled in this arm. The median age was 52.5 years (range 32 -73), 13 (65%) were premenopausal, and 55% had clinically positive lymph nodes. Tumors were MPHigh1 in 3 pts (15%) and SET2,3 index high in 16 pts (80%). The primary endpoint was met with 95% of study participants completing ≥75% of therapy. The T0 median Ki-67 was 10.5% (range 2-60%). At T1 (n=19) and T3 (n=18), median Ki-67 was 5% (range 0-35%) and 5% (range 0-45%), respectively. The 3-week rate of Ki-67 ≤10% at T1 was 61.5% in premenopausal and 71.4% in postmenopausal women. The rate of Ki-67 ≤10% at surgery was 81.8% in premenopausal and 57.1% in postmenopausal women. An mPEPI score of 0 was observed in 1 (5%) of participants. The median T0 FTV was 8.9 ccs (range 0.9 to 251.1). The median T3 FTV was 1.3 ccs (range 0 to 11.2) and the median change in FTV from T0 to T3 was -72.0% (range -88.5% to -61.6%). ctDNA analysis was performed in 17 pts longitudinally across 64 blood samples.10 pts had positive ctDNA at T0, with 7 converting to ctDNA undetectable during treatment with ENDX. 1/7 pts who was ctDNA negative at T0 became positive at T1 and then reverted to undetectable ctDNA. The other 6 pts remained ctDNA negative at all timepoints. The median ENDX T1 Css was 79.3 ng/mL (range 73.6 - 906.4 ng /mL). The most common side effects reported were Grade 1 hot flush (70%), nausea (40%), fatigue (40%), and insomnia (35%). Grade 2 side effects included fatigue (15%) and night sweats (5%). No dose reductions or discontinuations due to toxicity occurred. Conclusions: ENDX at 10 mg was well tolerated and demonstrated reductions in Ki-67, MRI FTV, and ctDNA. The ISPY2 EOP is currently enrolling patients to ENDX 40 mg/day (intended to dually target ERα and PKCβ1) in combination with abemaciclib (with and without OFS). Citation Format: K. V. Giridhar, M. P. Goetz, C. Yau, A. M. Wallace, C. Falkson, J. Boughey, M. Arora, E. Stringer-Reasor, C. Nangia, C. Gallagher, A. Elias, A. Zimmer, M. S. Trivedi, C. Omene, L. van 't Veer, L. Brown Swigart, G. L. Hirst, W. Symmans, A. D. Borowsky, N. Onishi, N. Hylton, C. Vakalvas, M. Wei, J. M. Reid, S. Alhafaji, N. Chen, R. M. Mukhtar, L. Huppert, O. Opopade, L. J. Esserman, A. Chein. Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-07-10.
Abstract PS2-07-17: Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic breast cancer (MBC) in TBCRC /AURORA US
Giridhar, K. V., Nenad, W. C., Ye, H., Wheeler, G. L., Hinoue, T., Michmerhuizen, A. R., Felsheim, B. M., Chandran, U. R., Kelly, B. J., Mardis, E. R., Laird, P. W., Balko, J. M., Garrido-Castro, A. C., Coppens, Sara E. , Bowen, J., Nanda, R., Lin, N. U., Anders, C. K., Isaacs, C., Tao, J. J., Anampa, J. D., Jahan, N., Huppert, L., DeMichele, A., Park, B. H., Vinayak, Shaveta , Delson, A. L., Magbanua, M. M., Balic, M., Parsons, H. A., Lee, A. V., Carey, L. A., Norton, Larrw, Wolff, A. C., Davidson, N. E., Krop, I., King, T. A., Perou, C. M., Hoadley, K. A., Network, Aurora US Metastases, Giridhar, K. V., Wheeler, G. L., Hinoue, T., Michmerhuizen, Anna R. , Felsheim, Brooke , Kelly, B. J., Mardis, E. R., Laird, P. W., Balko, J. M., Garrido-Castro, Ana C. , Nanda, Rita , Lin, N. U., Anders, Carey K. , Isaacs, Claudine , Anampa, J. D., Jahan, N., Huppert, L. A., DeMichele, Angie, Park, B. H., Delson, A. L., Magbanua, MJM, Balic, M., Parsons, H. A., Lee, A. V., Wolff, Antonio C , Davidson, N. E., Krop, Ian E. , King, T. A., Perou, Charles M. , Hoadley, K.A., Network, AURORA US

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-07-17-PS2-07-17

10.1158/1557-3265.sabcs25-ps2-07-17 Get It

Abstract Background: In MBC, CTC enumeration is highly prognostic for both progression free survival (PFS) and overall survival (OS). Multiparametric technologies enable for expanded phenotypic profiling of CTCs, including ER and HER2 assessment. Limited information is available on the concordance of CTC ER and HER2 levels compared to synchronously obtained tissue. We assessed the prognostic performance of CTC enumeration and phenotypic profiling of ER and HER2 on CTCs. Methods: The prospective, multi-institutional Aurora study enrolled pts with MBC of any subtype either at diagnosis of metastatic disease or at time of progression on any line of systemic therapy. Pts underwent a metastatic site biopsy, consented to archival primary tissue collection and donated blood samples serially every 3-4 months until progression. CTCs, from blood collected at study entry, were identified as nucleated, EpCAM+/ cytokeratin+/ CD45- cells using an automated imaging system (RareCyte, Seattle). ER and HER2 expression levels were measured by mean fluorescence intensity (MFI), with thresholds above 80 (ER) and 160 (HER2) considered positive. Comparisons were made to total RNAseq from paired metastatic tissue biopsies. PFS and OS were calculated from the time of study entry to last follow up or death. Results: Baseline CTC enumeration was performed in 154 pts. The most common clinical subtype was HR+/HER2- (59.7%), followed by HER2-positive (16.8%) and TNBC (15.5%). The median lines of prior therapy were 1 (range 0-10). At least 1 CTC was identified in 68/154 pts (44%), 30 (19%) had ≥ 5 CTCs, and 15 (9.7%) had CTC clusters. The median CTC value was 0 (0-877). The presence of CTCs (≥1 or ≥5) and CTC clusters was adversely associated with PFS and OS (Table 1 Table 1. CTC survival analyses Number Median PFS PFS HR (95% CI) Median OS OS HR (95% CI) Presence of CTC 0 CTC 86 7.37 (0.03 - 43.1) reference 20.72 (0.03 - 50.6) reference ≥ 1 CTC 68 4.7 (0.43 - 19.5) 1.65 (1.16-2.36) 12.04. (0.43-44.1) 2.13 (1.44-3.16) Presence of ≥ 5 CTC <5 CTC 124 7.7 (0.03 - 43.1) reference 19.31 (0.03 - 50.6) reference ≥ 5 CTC 30 2.88 (0.43 - 18.7) 1.77 (1.15 - 2.71) 5.74 (0.43 - 29.3) 3.59 (2.26-5.70) Presence of clusters 0 clusters 139 7.37 (0.03 - 43.1) reference 18.06 (0.03 - 50.6) reference ≥ 1 cluster 15 1.91 (0.43 - 18.7) 2.06 (1.16 - 3.68) 3.42 (0.43 - 18.7) 5.44 (2.94-10.09) ). Across all subtypes, the median CTC ER-MFI across was 36.2 (range 4.2-10,016.6) and the median HER2-MFI was 139.6 (range 4.2-2480.5). We observed high intra-patient heterogeneity of ER-MFI (CV: 0.65 [0.34-1.25]) and HER2-MFI (CV: 0.79 [0.42-1.54]). Clinical metastatic subtype from metastasis at study entry was available in 54/68 pts with CTCs. Pts with clinical ER+ MBC had a higher median ER-MFI compared to clinical TNBC (111.9 vs 68.6, p = 0.02). However, 11 pts (26.8%) with clinical ER+ MBC had all CTCs with an ER-MFI <80. Lower ER expression was observed in CTCs collected after prior exposure to a SERD (median ER-MFI: post-SERD [n=8] 27 vs post-aromatase inhibitor [n=4] 252, p<2.22e-16). No correlations were observed between the median CTC ER-MFI or HER2-MFI and paired tissue ESR1 or ERBB2 RNA expression (n=66). Conclusions: CTCs are strongly predictive of PFS and OS. CTC ER- and HER2-MFI were highly heterogeneous without clear correlation with bulk tissue RNA expression. The clinical impact of discordant clinical receptor status and CTC receptor status warrants further exploration. Citation Format: K. V. Giridhar, W. C. Nenad, H. Ye, G. L. Wheeler, T. Hinoue, A. R. Michmerhuizen, B. M. Felsheim, U. R. Chandran, B. J. Kelly, E. R. Mardis, P. W. Laird, J. M. Balko, A. C. Garrido-Castro, S. Coppens, J. Bowen, R. Nanda, N. U. Lin, C. K. Anders, C. Isaacs, J. J. Tao, J. D. Anampa, N. Jahan, L. Huppert, A. DeMichele, B. H. Park, S. Vinayak, A. L. Delson, M. M. Magbanua, M. Balic, H. A. Parsons, A. V. Lee, L. A. Carey, L. Norton, A. C. Wolff, N. E. Davidson, I. Krop, T. A. King, C. M. Perou, K. A. Hoadley, Aurora US Metastases Network. Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic breast cancer (MBC) in TBCRC /AURORA US [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-07-17.
Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study
Wirbel, Jakob , Saber, Wael, Andermann, Tessa M, Fei, Teng , Brooks, Erin F. , Doyle, Boryana , Pincus, Nathan B. , Bar, Merav , Bolaños-Meade, Javier, Chhabra, Saurabh, Choi, Sung Won , Clark, William, Elmariah, Hany, Jones, Richard J. , Jp, Levine, Logan, Brent R, Malki, Monzr M Al, Rashidi, Armin, Rezvani, Andrew R. , Riches, Marcie L., Runaas, Lyndsey, Sandhu, Karamjeet , Spahn, Ashley, Horowitz, MM, Hamadani, Mehdi, Kean, Leslie S. , Perales, Miguel-Angel, Bhatt, Ami S. , Choi, Sung Won , Elmariah, Hany , Andermann, Tessa M. , Saber, Wael , Martens, Michael J , Peled, Jonathan U , Andermann, Tessa M , Fei, Teng , Brooks, Erin F , Doyle, Boryana , Pincus, Nathan B , Jenq, Robert R , Bar, Merav , Bratrude, Brandi , Chhabra, Saurabh , Elmariah, Hany , Gooptu, Mahasweta , Holtan, Shernan , Al Malki, Monzr M , Murthy, Hemant S , Rashidi, Armin , Rezvani, Andrew R , Sung, Anthony D , van den Brink, Marcel R M , Kean, Leslie S , Perales, Miguel-Angel , Bhatt, Ami S , Choi, Sung Won , Saber, Wael , Martens, Michael J. , Peled, Jonathan U. , Jenq, Robert R. , Bolaños‐Meade, Javier , Clark, William, Das, Suman R. , Holtan, Shernan G. , Logan, Brent R. , Malki, Monzr M. Al , Murthy, Hemant S. , Rashidi, Armin , Riches, Marcie , Sung, Anthony D. , Hamadani, Mehdi , Perales, Miguel‐Angel

Mayo Clinic

No container title available | February 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.19.706769 | PMID 41756883 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for many hematological malignancies, but graft-versus-host disease (GVHD) is a common complication. Low gut microbiome diversity is associated with higher GVHD risk and shorter survival in multiple studies. Recently, the BMT CTN 1703 clinical trial demonstrated superiority of a GVHD-prophylaxis regimen including post-transplant cyclophosphamide (PTCy) compared to the standard prophylaxis (tacrolimus and methotrexate, Tac/MTX) in terms of GVHD-free, relapse-free survival at one year among reduced intensity conditioning allo-HCT recipients. However, the effect of PTCy on the gut microbiome and its association with clinical outcome have not been described. Here, we report on a companion randomized clinical controlled trial (BMT CTN 1801), which collected 2575 longitudinal stool samples from 304 study participants. Samples were obtained up to weekly up to day 84 post allo-HCT and at less frequent intervals thereafter, up to 2 years. Microbiome diversity and absolute microbial load were lower in the PTCy group compared to the Tac/MTX group on days 14–28 post-HCT. However, diversity at the timepoint closest to neutrophil engraftment was not significantly associated with non-relapse mortality after one year or other clinical outcomes, contrary to expectations from previous studies. Microbial domination events, when a single species exceeds 30% relative abundance, were comparable across treatment arms and reflected both pathogen blooms as well as less severe disruptions of the microbial community. Clostridium scindens and secondary bile acid metabolism pathways were less prevalent in the PTCy arm than in the Tac/MTX arm post-HCT, yet presence of secondary bile acid metabolism pathways was associated with a lower risk of chronic GVHD. Given that PTCy was associated with a greater disruption of the microbiome as measured by diversity, absolute microbial abundance, and bile acid metabolism capability, but better clinical outcomes overall, these data suggest that the importance of the microbiome in modulating the host immune systems after allo-HCT is specific to different types of GVHD prophylaxis.
Diels‐Alder Click Chemistry as a Dynamic‐Covalent Crosslinking Method in Spheroid‐Encapsulating Hydrogels for Cartilage Engineering
Looij, Sanne M. van de, Vasilopoulou, A , Spauwen, Lennard , Dikkenberg, Antoinette van den, Malda, Jos , Vermonden, Tina , van de Looij, Sanne M , Vermonden, Tina , Korpershoek, Jasmijn V. , Ruijter, Mylène de , Ravensteijn, Bas G. P. van

Mayo Clinic

Advanced Healthcare Materials | February 20, 2026 | Volume: 15 | Issue: 17 | Pages: No page available

10.1002/adhm.202505013 | PMID 41717958 Get It

ABSTRACT In cartilage tissue engineering, there is a growing interest in dynamic hydrogels that promote spheroid fusion and cartilaginous matrix deposition, while maintaining sufficient stability for long‐term construct maturation. In this study, Diels‐Alder click chemistry is employed as a dynamic‐covalent crosslinking method to create hydrogels composed of hyaluronic acid, gelatin, and PEG. By adjusting the pH during crosslinking, the tuneability of hydrogel stiffness and stability at pH values around the physiological pH of native cartilage is demonstrated. This pH modulation does not compromise hydrogel functionality, as encapsulated equine articular cartilage progenitor cell spheroids remain viable and functional for a culture period of 28 days. The hydrogel environment supports the deposition of cartilaginous extracellular matrix components, including collagens and sulphated glycosaminoglycans. Enhanced chondrogenesis and deposition of collagen type II are observed at higher spheroid concentrations, corresponding to inter‐spheroid distances of 100–150 µm following hydrogel swelling, compared to lower concentrations at a distance of >500 µm. To further improve construct robustness, the hydrogel constructs can be reinforced on day 1 with a melt electrowritten scaffold, increasing the compressive modulus 100‐fold by day 28 compared to non‐reinforced constructs, highlighting the potential of this system for engineering cartilage implants.
Endoscopist and Patients' Values and Preferences on Artificial Intelligence in Endoscopy: An Intercontinental Opinion Survey by the World Endoscopy Organization
Ahmad, O. F., Groof, A. de, Ali, Aman, Bassett, P., Engels, Megan , Hoogenboom, Sanne A. , Coelho‐Prabhu, N., Yu, H., Parasa, Sravanthi , Vivar, R. Mansilla, Mushtaq, Junaid , Neumann, Helmut, Thakkar, Shyam , Byrne, M. F., Hooft, J. E. van, Yano, Tomonori , Mori, Y., Yu, H , Yano, T , Groof, Albert Jeroen de, Bassett, P, Mwachiro, Michael , Mansilla‐Vivar, Rodrigo , Hooft, Jeanin E. van , Mori, Yuichi

Mayo Clinic

Digestive Endoscopy | February 20, 2026 | Volume: 38 | Issue: 2 | Pages: No page available

10.1111/den.70123 | PMID 41716045 Get It

ABSTRACT Background and Aims Artificial intelligence (AI) is increasingly integrated into gastrointestinal (GI) endoscopy, yet limited data exist on how patients and endoscopists perceive its use. This study aimed to evaluate users' values and preferences regarding AI in endoscopy to support effective implementation and inform guideline development. Methods As part of the World Endoscopy Organization (WEO) AI committee initiatives, two structured international surveys were conducted—one for patients and one for practicing endoscopists. Thirteen AI‐related statements were presented to patients via an established online platform, while 23 statements were shared with endoscopists through professional networks. Responses were captured using 5‐point Likert scales and analyzed with non‐parametric tests, including subgroup comparisons by age, gender, and endoscopic experience. Results A total of 1237 patients and 476 endoscopists participated. Most patients supported AI in image analysis (75.5%) but emphasized the need for endoscopist oversight (92.3%). Among endoscopists, 90.3% believed AI improves endoscopy quality, and 85.3% believed it benefits outcomes. Concerns were raised about liability (47%), operator dependency (34.8%), and procedure time (49%). Most respondents felt primary responsibility for AI‐related errors should rest with the endoscopist. Younger and male patients reported greater trust in AI. Conclusions Patients and endoscopists are generally supportive of AI in GI endoscopy, especially as an adjunct to human expertise. However, key concerns—including accountability, trust, and clinical integration—must be addressed to ensure responsible and effective adoption.